235 related articles for article (PubMed ID: 24084325)
1. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Laurin LP; Nachman PH; Desai PC; Ataga KI; Derebail VK
Nephrol Dial Transplant; 2014 Jun; 29(6):1211-8. PubMed ID: 24084325
[TBL] [Abstract][Full Text] [Related]
2. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
Drawz P; Ayyappan S; Nouraie M; Saraf S; Gordeuk V; Hostetter T; Gladwin MT; Little J
Clin J Am Soc Nephrol; 2016 Feb; 11(2):207-15. PubMed ID: 26672090
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease and albuminuria in children with sickle cell disease.
McPherson Yee M; Jabbar SF; Osunkwo I; Clement L; Lane PA; Eckman JR; Guasch A
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2628-33. PubMed ID: 21940843
[TBL] [Abstract][Full Text] [Related]
5. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Fitzhugh CD; Wigfall DR; Ware RE
Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
[TBL] [Abstract][Full Text] [Related]
6. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis.
Khargekar N; Banerjee A; Athalye S; Mahajan N; Kargutkar N; Tapase P; Madkaikar M
Syst Rev; 2024 Feb; 13(1):60. PubMed ID: 38331925
[TBL] [Abstract][Full Text] [Related]
7. Sickle Cell Nephropathy in the Pediatric Population.
Olaniran KO; Eneanya ND; Nigwekar SU; Vela-Parada XF; Achebe MM; Sharma A; Thadhani RI
Blood Purif; 2019; 47(1-3):205-213. PubMed ID: 30517931
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease.
McKie KT; Hanevold CD; Hernandez C; Waller JL; Ortiz L; McKie KM
J Pediatr Hematol Oncol; 2007 Mar; 29(3):140-4. PubMed ID: 17356390
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
[No Abstract] [Full Text] [Related]
10. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
Fitzhugh CD; Hsieh MM; Allen D; Coles WA; Seamon C; Ring M; Zhao X; Minniti CP; Rodgers GP; Schechter AN; Tisdale JF; Taylor JG
PLoS One; 2015; 10(11):e0141706. PubMed ID: 26576059
[TBL] [Abstract][Full Text] [Related]
11. Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease.
Tehseen S; Joiner CH; Lane PA; Yee ME
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612449
[TBL] [Abstract][Full Text] [Related]
12. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Gladwin MT; Sachdev V; Jison ML; Shizukuda Y; Plehn JF; Minter K; Brown B; Coles WA; Nichols JS; Ernst I; Hunter LA; Blackwelder WC; Schechter AN; Rodgers GP; Castro O; Ognibene FP
N Engl J Med; 2004 Feb; 350(9):886-95. PubMed ID: 14985486
[TBL] [Abstract][Full Text] [Related]
14. Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors.
Bolarinwa RA; Akinlade KS; Kuti MA; Olawale OO; Akinola NO
Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):171-5. PubMed ID: 22237246
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Sasongko TH; Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2013 Mar; (3):CD009191. PubMed ID: 23543572
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of albuminuria in sickle cell disease patients at the Campus university hospital of Lome, Togo].
Layibo Y; Kuéviakoé IM; Padaro E; Magnang H; Vovor A; Agbonon A
Ann Biol Clin (Paris); 2019 Feb; 77(1):79-86. PubMed ID: 30799301
[TBL] [Abstract][Full Text] [Related]
18. Combined hydroxyurea and ET
Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.
Han J; Bhat S; Gowhari M; Gordeuk VR; Saraf SL
Pharmacotherapy; 2016 Nov; 36(11):1166-1172. PubMed ID: 27639254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
